Business / Finance

RSS

Zimmer fourth quarter net sales increase 2.5% to $1.13 billion

Zimmer Holdings, Inc. today reported financial results for the quarter and year ended December 31, 2010. The Company reported fourth quarter net sales of $1.13 billion, an increase of 2.5% reported and 3.0% constant currency over the fourth quarter of 2009.

27 Jan 2011

Fresenius Medical Care prices US$ senior notes

Fresenius Medical Care AG & Co. KGaA, the world's largest provider of dialysis products and services, today announced the pricing of US$-denominated and €-denominated senior unsecured notes in the principal amounts of US$650 million and €300 million, respectively, both due 2021.

27 Jan 2011

Mead Johnson's 2010 GAAP net earnings increase to $2.20 per diluted share

"We concluded the year on a strong note reporting record sales and earnings for 2010," said Chief Executive Officer Stephen W. Golsby. "The year unfolded as expected with Asia and Latin America continuing to deliver double-digit sales growth and the North America/Europe segment growing in the low single-digits.

27 Jan 2011

Baxter fourth quarter net income declines 26% to $423 million

Baxter International Inc. today announced its financial results for the fourth quarter of 2010, and provided its financial outlook for the first quarter and full-year 2011.

From Baxter International Inc. 27 Jan 2011

Despite reimbursement cuts the diagnostic imaging market to grow at 5% over next five years: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, although the overall diagnostic imaging market has been limited by reimbursement cuts and poor economic conditions, the next five years will see unit growth of approximately 5%.

27 Jan 2011

PSS World Medical third quarter consolidated earnings per diluted share increase 16.6% to $0.35

PSS World Medical, Inc. announced today its results for the fiscal 2011 third quarter ended December 31, 2010.

27 Jan 2011

NuGEN, Caliper enter co-marketing agreement in next generation sequencing sample preparation methods

NuGEN Technologies, Inc. and Caliper Life Sciences, Inc. today announced a co-marketing agreement for the development of automated methods for next generation sequencing sample preparation on Caliper's Sciclone® NGS Workstation.

27 Jan 2011

Merck Canada invests in CQDM to support biopharmaceutical research

Merck Canada has renewed its partnership with the Quebec Consortium for Drug Discovery by investing a further $5 million over five years in the organization so it can continue its support of biopharmaceutical research in Quebec.

27 Jan 2011

Healthcare at Home acquires Sciensus

Healthcare at Home Ltd, Europe's leading international provider of home-based healthcare and specialty pharmacy services, is today pleased to announce that it has acquired Sciensus Ltd, a provider of health informatics for clients across the NHS and the pharmaceutical industry.

27 Jan 2011

QIAGEN announces formation of subsidiary in India

QIAGEN today announced the formation of its India subsidiary, QIAGEN India Pvt. Ltd., and the beginning of direct sales in the country. Until now, QIAGEN products have been sold in India through distributor partnerships.

From QIAGEN Manchester Limited 27 Jan 2011

FDA, Simulations Plus sign RCA to develop QSAR toxicity models

Simulations Plus, a leading provider of software for pharmaceutical discovery and development, announced that the U.S. Food and Drug Administration and Simulations Plus have signed a five-year research collaboration agreement to work together to develop Quantitative Structure-Activity Relationship toxicity models for FDA regulatory and research applications.

27 Jan 2011

Alcon fourth quarter sales raise 5.7% to $1.81 billion in 2010

Alcon, Inc. reported that global sales rose 5.7 percent to $1.81 billion for the fourth quarter of 2010. Revenue from acquisitions added 100 basis points to sales growth in the quarter, while foreign currency fluctuations reduced reported sales growth by 20 basis points.

27 Jan 2011

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2010.

27 Jan 2011

Teva announces acquisition of Corporación Infarmasa

Teva Pharmaceutical Industries Ltd. announced today the acquisition of Corporación Infarmasa, a top ten pharmaceutical company in Perú, from The Rohatyn Group and Altra Investments.

27 Jan 2011

It may not be the end for employer-sponsored insurance

A new study finds the effects of health care reform to be minimal on employer-sponsored insurance, despite criticism that changes to how insurance premiums are calculated will force employers to stop offering coverage.

27 Jan 2011

Inviragen completes memorandum of understanding with Duke-NUS

Inviragen, and the Duke-National University of Singapore Graduate Medical School announced today that they have completed a memorandum of understanding to establish a partnership between the two organizations.

27 Jan 2011

Nexstim closes additional equity financing for approximately EUR 11.4 million

Nexstim Oy, a medical device company commercializing noninvasive brain diagnostic and therapy technologies, today announced that it has closed on additional equity financing of approximately EUR 11.4 million.

27 Jan 2011

CyDex stockholders approve merger with Ligand

CyDex Pharmaceuticals, Inc. today announced that its stockholders have voted to approve an Agreement and Plan of Merger between CyDex and Ligand Pharmaceuticals Incorporated and that closing of the transaction has taken place. CyDex will continue its business operations, based in Lenexa, Kansas, as a wholly owned subsidiary of Ligand.

27 Jan 2011

Anapharm Europe, PharmaNet officially terminate joint venture

PharmaNet Development Group, and Anapharm Europe, S.L., both leading providers of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announced that their joint venture for the collaborative provision of bioanalytical services officially ended December 22, 2010.

27 Jan 2011

Teva, APP enter agreement for launch of generic Gemzar

Teva Pharmaceutical Industries Ltd. and APP Pharmaceuticals, Inc. announced today the commercial launch of Gemcitabine HCI for Injection in 200 mg and 1 g single dose vials, the generic version of Gemzar®, in the United States, pursuant to a commercialization, manufacture and supply agreement signed by the two companies.

26 Jan 2011